27 research outputs found
Genetic variants in combination with early partial improvement as a clinical utility predictor of treatment outcome in major depressive disorder: The result of two pooled RCTs
Pharmacogenetics may allow for a personalized treatment, but a combination with clinical variables may further enhance prediction. In particular, in the present paper, we investigated early partial improvement (EPI) defined as 20% or more improvement by rating scales 2weeks after treatment, in combination with selected gene variants as a predictor of treatment outcome in patients with major depressive disorder. Two randomized controlled trials with 168 Japanese depressed patients were used. A stepwise multiple linear regression model with HAM-D score change at week 6 as the dependent variable and genotypes, EPI, baseline HAM-D score, age and sex as independent variables was performed in paroxetine, fluvoxamine and milnacipran, respectively, to estimate the prediction of HAM-D change at week 6. In the paroxetine sample, only EPI (P<0.001) was significantly associated with HAM-D change (n=81, R 2 =0.25, P<0.001). In the fluvoxamine sample, 5-HTTLPR La/Lg, S (P=0.029), FGF2 rs1449683C/T (P=0.013) and EPI (P=0.003) were associated with HAM-D change (n=42, R 2 =0.43, P<0.001). In the milnacipran sample, HTR-1A-1019C/G (P=0.001), ADRA2A-1297C/G (P=0.028) and EPI (P<0.001) were associated with outcome (n=45, R 2 =0.71, P<0.001). EPI in combination with genetic variants could be a useful predictor of treatment outcome and could strengthen the practical use of pharmacogenetic data in clinical practice
No Association of TPH1 218A/C Polymorphism with Treatment Response and Intolerance to SSRIs in Japanese Patients with Major Depression
[5-HT1A gene polymorphisms contributed to antidepressant response in major depression].
Variability in antidepressant response is due to genetic and environmental factors. Among genetic factors, the ones controlling for availability of the drug at the target site are interesting candidates. Rs6295C/G SNP in the 5-HT1A gene (HTR1A) has been found to affect the expression and function of HTR1A. In fact rs6295C/G is in strong linkage disequilibrium with other polymorphisms of HTR1A suggesting that those functional effects could be associated with polymorphisms other than or together with the synonymous rs6295C/G. In the present study we examined the possible association of a panel of markers in strong linkage disequilibrium of HTR1A with SSRI/SNRI response in 137 Japanese major depression subjects followed for 6 weeks. We observed a significant association of better response to antidepressant in rs10042486C/C (P < 0.0001), rs6295G/G (P < 0.0001) and rs1364043T/T (P = 0.018) genotype carriers, independently from clinical variables. Furthermore minor allele homozygous carriers in all these 3 SNPs were associated with treatment response by various assessments such as HAM-D score change over time (P = 0.001), week 2 (P < 0.0001), 4 (P = 0.007), and 6 (P = 0.048) as well as response rate (P = 0.0005) and remission rate (P = 0.004). We also pointed out the genotyping mis-definition of rs6295C/G in the previous four papers
Antidepressant response and intolerance to SSRI is not influenced by G-protein beta3 subunit gene C825T polymorphism in Japanese major depressive patients
Effect of basic fibroblast growth factor (FGF2) gene polymorphisms on SSRIs treatment response and side effects
Effect of 5-HT1A gene polymorphisms on antidepressant response in major depressive disorder
Variability in antidepressant response is due to genetic and
environmental factors. Among genetic factors, the ones controlling
for availability of the drug at the target site are interesting
candidates. Rs6295C/G SNP in the 5-HT1A gene (HTR1A) has
been found to affect the expression and function of HTR1A. In
fact rs6295C/G is in strong linkage disequilibrium with other
polymorphisms of HTR1A suggesting that those functional
effects could be associated with polymorphisms other than or
together with the synonymous rs6295C/G. In the present study
we examined the possible association of a panel of markers in
strong linkage disequilibrium of the HTR1A with SSRI/SNRI
response in 137 Japanese major depression subjects followed for
6 weeks. We observed a significant association of better response
to antidepressant in rs10042486C/C (P<0.0001), rs6295G/G
(P<0.0001) and rs1364043T/T (P¼0.018) genotype carriers
(minor allele homozygotes), independently from clinical variables.
Furthermore minor allele homozygous carriers in all these
three SNPs were associated with treatment response by various
assessment such as HAM-D score change over time (P¼0.001),
week 2 (P<0.0001), 4 (P¼0.007), and 6 (P¼0.048) as well as
response rate (P¼0.0005) and remission rate (P¼0.004). We
also pointed out the genotyping mis-definition of rs6295C/G in
the previous four articles. In conclusion, this is the first study that
reports a significant association of antidepressant response with
rs10042486C/T and rs1364043T/G variants of HTR1A and also
with rs10042486–rs6295–rs1364043 combination. This finding
adds an important information for the pathway of detecting the
genetics of antidepressant response even if results must be
verified on larger samples